Robyn Klein, LMSW | |
30 Burnor Dr, Highgate Center, VT 05459-4177 | |
(757) 918-9317 | |
Not Available |
Full Name | Robyn Klein |
---|---|
Gender | Female |
Speciality | Social Worker - Clinical |
Location | 30 Burnor Dr, Highgate Center, Vermont |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1598437857 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
1041C0700X | Social Worker - Clinical | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Robyn Klein, LMSW 30 Burnor Dr, Highgate Center, VT 05459-4177 Ph: (757) 918-9317 | Robyn Klein, LMSW 30 Burnor Dr, Highgate Center, VT 05459-4177 Ph: (757) 918-9317 |
News Archive
Emergency physicians in Michigan propose a new health care delivery model for rural populations that depends on a partnership between emergency medicine and primary care and seeks to reverse the trend of failing health in underserved parts of the country.
National Jewish Health has received a US patent for a method of detecting autoimmune chronic urticaria, which will help assure many patients that dramatic changes in lifestyle are not needed to treat the condition.
Roche NimbleGen has announced that imaGenes GmbH, a Berlin-based genomics & proteomics specialist, has achieved status as a Certified Service Provider (CSP) of NimbleGen microarrays for Chromatin Immunoprecipitation (ChIP-chip). imaGenes GmbH has passed a rigorous ChIP-chip certification to officially become part of the Roche NimbleGen Certified Service Provider Program.
Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, announced today that it has submitted supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration seeking approval for the use of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] to treat children under the age of 12 with hemophilia A and for use in surgical settings.
ArtVentive Medical Group, announced today a ten million dollar financing agreement with a European financial group. A firm commitment for the first tranche of $1,950,000 is at $.90 per share with the remainder of the financing to be priced at not less than $.90 per share.
› Verified 9 days ago